Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer
Figure 3
Reduction of Luciferase activity in human and hamster pancreatic carcinoma cell lines due to cotransfection with the DTA-H19 vector. The therapeutic potential of the DTA-H19 vector in different cell lines was measured as a reduction of Luciferase activity. (a) 90000 cells/well were cotransfected with 3 g of Luc-SV40 plasmid and the indicated amounts of DTA-H19. The luciferase assay was performed 48 hours after transfection. (c) 70000 cells/well were cotransfected with 3 g of Luc-SV40 plasmid and the indicated concentrations of DTA-H19. Transfection experiments were stopped after 24 hours, and reporter gene activity was assessed. The reduction in the Luc-SV40 activity in the cotransfected cells was compared to cells transfected with Luc-SV40 alone for each cell line. Bar graphs represent the relative Luciferase activity of the H19 promoter when cells were transfected with Luc-H19 plasmid.
